Table 1.
Imatinib-naive and imatinib-treated CML-CP–like mice harbor leukemia clones expressing imatinib-resistant BCR-ABL1 kinase mutations
| Mice* | Assay | Sensitivity | Detection† | Mutations |
|---|---|---|---|---|
| Untreated | D-HPLC | 10−2 to 10−3 (wt:mut mRNA) | 0/7 | — |
| Imatinib | 0/5 | — | ||
| Untreated | ASO-PCR | 10−3 (wt:mut mRNA); 10−3 (cells) | 1/7 | E255K, T315I |
| Imatinib | 1/5 | T315I | ||
| Untreated | Resistant colonies + sequencing | 10−6 cells | 5/7 | E255K, T315I, H396P |
*
Leukemic mice were untreated or treated with imatinib as described in “Methods.”
†
Number of mice with mutations/total number of mice analyzed.